Skip to content
Search AI Powered

Latest Stories

Lenmeldy, a lifesaving gene therapy, now the world's most expensive drug

Striking about 1 in 100,000 newborns, MLD is a rare, rapidly worsening, and fatal nervous system disorder.

Lenmeldy, a lifesaving gene therapy, now the world's most expensive drug

Lenmeldy, a new gene therapy for the rare and fatal childhood disease metachromatic leukodystrophy (MLD), has become the world's most expensive drug, at a whopping $4.25 million (£3.350 million).

MLD is a brutal illness that strikes toddlers and affects their ability to walk and talk. It's a heartbreaking reality for families, with roughly half of the afflicted children succumbing to the disease, while the others live on in a vegetative state.


However, MLD is also incredibly rare, affecting only around 40 children annually in the United States. This very rarity lies at the heart of the soaring price tags associated with new gene therapies like Lenmeldy. Consider the economics: Orchard employs a staff of 160, a stark contrast to the limited number of children they can treat over several years.

“My heart wants to talk about what an effect this therapy has had on these children. Without it, they will die very young or live for many years in a vegetative state. But kids who get the gene therapy, mostly end up being able to walk and do well cognitively. The ones we treat are going to school, they’re playing sports, and they are able to tell their stories,” says Orchard’s chief medical officer, Leslie Meltzer.

While the manufacturer, Orchard Therapeutics, justifies this astronomical cost by highlighting the treatment's potential to cure a deadly disease, affordability and accessibility remain major concerns.

This raises questions about the commercial viability of Lenmeldy, even at its current price. Experts predict a challenging journey, citing the past struggles of gene therapies on the market. The European experience with Lenmeldy, approved there three years ago at a slightly lower price, reflects this. Orchard generated a mere $12.7 million (£10.04 million) from sales for most of last year, a clear indication of the limited number of children treated.

Despite the financial concerns, Lenmeldy offers a glimmer of hope. The treatment works by adding a missing gene to a child's bone marrow cells, effectively reversing the root cause of the disease in the brain. Children who participated in trials that began in 2010 are now living normal lives, a testament to the therapy's effectiveness.

Independent groups also support the value of Lenmeldy. The Institute for Clinical and Economic Review, which assesses drug value, estimates the treatment to be cost-effective within a range of £1.8 million to £3.08 million. However, super-high prices can signal economic unsustainability. A previous record holder, the gene therapy Glybera for a different condition, was purchased only once before being pulled from the market due to its $1 million price tag, which couldn't be justified by its limited effectiveness.

gene therapy Five specialised treatment centres being qualified across the US to minimise travel burden on eligible patients and their families (Representative image: iStock)

Hemgenix, a £2.7 million gene therapy for haemophilia, held the title of the most expensive drug until Lenmeldy's arrival. Although these therapies were envisioned to generate billions in sales, news reports suggest a lower-than-expected uptake.

Orchard itself discontinued another gene therapy, Strimvelis, which offered a cure for a specific immune deficiency. The limited patient pool and the existence of an alternative treatment proved to be insurmountable hurdles, even with a money-back guarantee. Orchard was subsequently acquired by the Japanese drug company Kyowa Kirin.

The success of Lenmeldy hinges on early testing. Once symptoms develop, it might be too late. Currently, many cases are identified only because an older sibling succumbed to the inherited condition.

Early detection through newborn screening programs could be a game-changer, allowing for timely intervention and potentially saving countless lives. A decision on newborn screening for MLD is expected in May 2024.

Amy Price, a parent who lost one child to MLD but saved two others with Lenmeldy, exemplifies the human impact of this treatment. Her two treated children are now thriving teenagers.

While acknowledging the high cost, this treatment emphasises the long-term benefits compared to the financial burden of caring for an untreated child.

Lenmeldy represents a significant breakthrough in gene therapy. However, its high cost and the rarity of the disease it treats create significant challenges. Increased access through early testing and insurance coverage will be crucial for maximising the life-saving potential of this groundbreaking treatment.

Teddi Shaw, a toddler with a rare genetic disease, became the first child in the UK in 2023 to receive life-saving gene therapy on the NHS. last year, in February. The treatment, Libmeldy, is very expensive but could not help Teddi's older sister Nala, who was diagnosed too late.

Both girls have MLD, a fatal condition that attacks the brain and nervous system. Nala started showing symptoms first, like uncoordinated walking and tremors. The doctors initially dismissed the parents' concerns but later confirmed it was MLD.

Sadly, by the time Nala was diagnosed, the new gene therapy was no longer an option for her. Now terminally ill, Nala can only receive supportive care.

More For You

Unlocking ancient healing: The power and precision of Vedic mantras

Divya Chikitsa Mantras use sound and vibrations to produce profound healing and transformational effects

Unlocking ancient healing: The power and precision of Vedic mantras

Ashwini Guruji

You may have heard of Sanjeevani Vidya, bestowed by Guru Shukracharya, which could revive the dead, or the Sanjeevani Buti that restored Lakshman’s life. Tales like Madhu Vidya, enabling immortality, and the Ashvini Kumars’ Chyawanprasha, rejuvenating Sage Chyawan, are not mere stories but the practical achievements of Vedic rishis. Masters of Creation, they understood the human body as a microcosm of the universe. The proof of these ancient sciences lies in modern scientific discoveries, many rooted in Vedic shastras. Visit www.dhyanfoundation.com to explore this connection.

Though much of this ancient knowledge has been lost in Kaliyuga and many herbs have become extinct, fragments remain accessible and potent. Divya Chikitsa Mantras from Sanatan Kriya are one such gem. These mantras use sound and vibrations to produce profound healing and transformational effects. Comprising seven mantras, they unclog energy channels (nadis), activate specific centers, and channel divine energies into the practitioner.

Keep ReadingShow less
nhs-hospital-getty

NHS faces pressure as flu admissions rise sharply

FLU cases in the country have surged, with over 5,000 hospital admissions last week, marking a sharp increase as the NHS faces pressure from a winter quad-demic of flu, Covid, respiratory syncytial virus (RSV), and norovirus.

According to The Times, flu admissions rose from 4,102 on Christmas Day to 5,074 by 29 December.

Keep ReadingShow less
AI-diabetes-risk-tool-iStock

World's first AI diabetes risk tool to be tested by NHS in 2025

THE NHS in England is set to launch a world-first trial of an artificial intelligence (AI) tool that predicts the risk of developing type 2 diabetes up to 13 years before symptoms appear.

The trial, scheduled for 2025, will take place at Imperial College Healthcare NHS Trust and Chelsea and Westminster Hospital NHS Foundation Trust, The Guardian reported.

Keep ReadingShow less
Agni: The sacred science of fire and its transformative power

Fire (agni) holds a profound significance in Vedic rituals

iStock

Agni: The sacred science of fire and its transformative power

Ashwini Guruji

Agni, the first word of the Rig Veda, holds a profound significance. It is, in fact, a wondrous element. While most are familiar with fire for its heat and light, very few understand that fire sustains our body and plays a pivotal role in cleansing it and the surrounding elements. Even fewer appreciate its role as a medium to connect with the Devlok (realm of the divine), and hardly anyone explores its potential to manifest changes within and around them. Dhyan Ashram is one such rare place in today’s world where sadhaks (practitioners) experiment with and experience the extraordinary properties of fire.

In Vedic times, yagyas were a routine practice. They were not mere rituals but a precise science designed to invoke and channel the forces of Creation through the medium of fire. The Vedic Shastras detail nearly 400 types of yagyas, each with a specific purpose.

Keep ReadingShow less
genomics-iStock

A recent RHO review highlighted significant gaps in health equity data for genomic services. (Representational image: iStock)

NHS study to tackle inequalities in access to genomic medicine

THE NHS Race and Health Observatory (RHO) and NHS England have launched an 18-month research project to address disparities faced by ethnic minority groups in accessing genomic medicine.

The initiative will examine racial and ethnic biases in the NHS Genomic Medicine Service (GMS) through national and regional assessments of health inequalities.

Keep ReadingShow less